Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study
Ivar Hompland(Oslo University Hospital), Sigbjørn Smeland(Oslo University Hospital), Gerda Hofmann-Wackersreuther(Paracelsus Medizinische Privatuniversität), Daniel Baumhoer(University Hospital of Basel), Torsten Keßler(University Hospital Münster), Lina Hansson(Sahlgrenska University Hospital), Claudia Blattmann(Olgahospital), R. Biagini(Tumori Foundation), Stefan Bielack(Olgahospital), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Elisabetta Setola(Istituto Ortopedico Rizzoli), Virginia Ferraresi(Cancer Institute (WIA)), Alessandro Comandone(Ospedale Humanitas Gradenigo), Bodil Bjerkehagen(Oslo University Hospital), Mikael Eriksson(Herlev Hospital), Fatime Krasniqi(University Hospital of Basel), Rossella Bertulli(Fondazione IRCCS Istituto Nazionale dei Tumori), Peter Reichardt(Helios Hospital Berlin-Buch), Anne Flörcken(Humboldt-Universität zu Berlin), Stefanie Hecker‐Nolting(University College London Hospitals NHS Foundation Trust), Gaetano Apice, Marco Gambarotti(Istituto Ortopedico Rizzoli), Emanuela Palmerini(Istituto Ortopedico Rizzoli), Piero Picci(Istituto Ortopedico Rizzoli), Davide María Donati(University of Modena and Reggio Emilia), Pietro Ruggieri(University of Padua), Kirsten Sundby Hall(Oslo University Hospital), Thomas Kühne(University Children’s Hospital Basel), Stefano Ferrari(University of Bergamo), Björn-N. Heydrich(University Hospital Schleswig-Holstein), Otte Brosjö(Karolinska University Hospital), Rudolf Schwarz(Universität Hamburg), Leo Kager(University of Vienna), Matthias Kevric(Universität Hamburg), Eric L. Staals(Istituto Ortopedico Rizzoli)
Cited by 34
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k